The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 4, 2011, Pages 687-694

  Sun, Jong Mu ^a   Won, Young Woong ^a   Kim, Seung Tae ^a   Kim, Jung Hoon ^a   Choi, Yoon La ^a   Lee, Jeeyun ^a   Park, Yeon Hee ^a   Ahn, Jin Seok ^a   Park, Keunchil ^a   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Activating mutation; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXON; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOMATIC MUTATION; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EXONS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY;

EID: 79954450183     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0928-2     Document Type: Article

References (24)

1. MJ Ahn BB Park JS Ahn SW Kim HT Kim JS Lee JH Kang JY Cho HS Song SH Park CH Sohn SW Shin JH Choi CS Ki CK Park AJ Holmes PA Janne K Park 2008 Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 14 3860 3866 18559606 10.1158/1078-0432.CCR-07-4608 1:CAS:528:DC%2BD1cXntlWrt7w%3D
2. H Asahina K Yamazaki I Kinoshita N Sukoh M Harada H Yokouchi T Ishida S Ogura T Kojima Y Okamoto Y Fujita H Dosaka-Akita H Isobe M Nishimura 2006 A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br J Cancer 95 998 1004 17047648 10.1038/sj.bjc.6603393 1:CAS:528:DC%2BD28XhtVyitbfO (Pubitemid 44606825)
3. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai K Noda I Takata E Smit S Averbuch A Macleod A Feyereislova RP Dong J Baselga 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2237 2246 12748244 10.1200/JCO.2003.10.038 1:CAS:528:DC%2BD2cXpsVGqu7w%3D (Pubitemid 46621858)
4. A Inoue T Suzuki T Fukuhara M Maemondo Y Kimura N Morikawa H Watanabe Y Saijo T Nukiwa 2006 Prospective phase ii study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 3340 3346 16785471 10.1200/JCO.2005.05.4692 1:CAS:528:DC%2BD28Xot1Kis7g%3D (Pubitemid 46638887)
5. DM Jackman BY Yeap LV Sequist N Lindeman AJ Holmes VA Joshi DW Bell MS Huberman B Halmos MS Rabin DA Haber TJ Lynch M Meyerson BE Johnson PA Janne 2006 Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib Clin Cancer Res 12 3908 3914 16818686 10.1158/1078-0432.CCR-06-0462 1:CAS:528:DC%2BD28XmsValt7k%3D (Pubitemid 44078074)
6. DM Jackman VA Miller L-A Cioffredi BY Yeap PA Jänne GJ Riely MG Ruiz G Giaccone LV Sequist BE Johnson 2009 Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res 15 5267 5273 19671843 10.1158/1078-0432.CCR-09- 0888 1:CAS:528:DC%2BD1MXpvFeitLs%3D
7. H Jiang 2009 Overview of gefitinib in non-small cell lung cancer: an Asian perspective Jpn J Clin Oncol 39 137 150 19088154 10.1093/jjco/hyn139
8. PA Jänne AM Borras Y Kuang AM Rogers VA Joshi H Liyanage N Lindeman JC Lee B Halmos EA Maher RJ Distel M Meyerson BE Johnson 2006 A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening Clin Cancer Res 12 751 758 16467085 10.1158/1078-0432.CCR-05-2047 (Pubitemid 43259854)
9. M McCracken M Olsen MS Chen Jr A Jemal M Thun V Cokkinides D Deapen E Ward 2007 Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities CA Cancer J Clin 57 190 205 17626117 10.3322/canjclin.57.4.190 (Pubitemid 47312080)
10. T Mitsudomi S Morita Y Yatabe S Negoro I Okamoto J Tsurutani T Seto M Satouchi H Tada T Hirashima K Asami N Katakami M Takada H Yoshioka K Shibata S Kudoh E Shimizu H Saito S Toyooka K Nakagawa M Fukuoka 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121 128 20022809 10.1016/S1470-2045(09) 70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
11. TS Mok YL Wu S Thongprasert CH Yang DT Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose Y Nishiwaki Y Ohe JJ Yang B Chewaskulyong H Jiang EL Duffield CL Watkins AA Armour M Fukuoka 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
12. CR Newton A Graham LE Heptinstall SJ Powell C Summers N Kalsheker JC Smith AF Markham 1989 Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucl Acids Res 17 2503 2516 2785681 10.1093/nar/17.7.2503 1:CAS:528:DyaL1MXktFyktbs%3D (Pubitemid 19103235)
13. S Park AJ Holmes-Tisch EY Cho YM Shim J Kim HS Kim J Lee YH Park JS Ahn K Park PA Janne MJ Ahn 2009 Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer J Thorac Oncol 4 809 815 19487967 10.1097/JTO.0b013e3181a94af4
14. R Perez-Soler A Chachoua LA Hammond EK Rowinsky M Huberman D Karp J Rigas GM Clark P Santabarbara P Bonomi 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238 3247 15310767 10.1200/JCO.2004.11.057 1:CAS:528:DC%2BD2cXpsVGrsLg%3D (Pubitemid 41103678)
15. GJ Riely 2008 The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations Lung Cancer 60 Suppl 2 S19 S22 18513580 10.1016/S0169-5002(08)70101-6 (Pubitemid 351726033)
16. GJ Riely W Pao D Pham AR Li N Rizvi ES Venkatraman MF Zakowski MG Kris M Ladanyi VA Miller 2006 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 12 839 844 16467097 10.1158/1078-0432.CCR-05-1846 1:CAS:528:DC%2BD28XhtFeiurk%3D (Pubitemid 43259866)
17. R Rosell T Moran C Queralt R Porta F Cardenal C Camps M Majem G Lopez-Vivanco D Isla M Provencio A Insa B Massuti JL Gonzalez-Larriba L Paz-Ares I Bover R Garcia-Campelo MA Moreno S Catot C Rolfo N Reguart R Palmero JM Sanchez R Bastus C Mayo J Bertran-Alamillo MA Molina JJ Sanchez M Taron 2009 Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 958 967 19692684 10.1056/NEJMoa0904554 1:CAS:528:DC%2BD1MXhtVOqsL7M
18. LV Sequist 2008 First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients J Thorac Oncol 3 S143 S145 18520299 10.1097/JTO.0b013e318174e981 (Pubitemid 351786746)
19. LV Sequist RG Martins D Spigel SM Grunberg A Spira PA Janne VA Joshi D McCollum TL Evans A Muzikansky GL Kuhlmann M Han JS Goldberg J Settleman AJ Iafrate JA Engelman DA Haber BE Johnson TJ Lynch 2008 First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J Clin Oncol 26 2442 2449 18458038 10.1200/JCO.2007.14.8494 1:CAS:528:DC%2BD1cXnsVKhtbk%3D
20. H Shigematsu L Lin T Takahashi M Nomura M Suzuki II Wistuba KM Fong H Lee S Toyooka N Shimizu T Fujisawa Z Feng JA Roth J Herz JD Minna AF Gazdar 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339 346 15741570 10.1093/jnci/dji055 1:CAS:528:DC%2BD2MXitV2jsb4%3D (Pubitemid 40425952)
21. HR Shin KW Jung YJ Won JG Park 2004 2002 annual report of the Korea central cancer registry Cancer Res Treat 36 103 114 20396549 10.4143/crt.2004.36.2.103
22. K Sugio H Uramoto T Onitsuka M Mizukami Y Ichiki M Sugaya M Yasuda M Takenoyama T Oyama T Hanagiri K Yasumoto 2009 Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations Lung Cancer 64 314 318 18992959 10.1016/j.lungcan.2008.09.010
23. H Yamamoto S Toyooka T Mitsudomi 2009 Impact of EGFR mutation analysis in non-small cell lung cancer Lung Cancer 63 315 321 18760859 10.1016/j.lungcan. 2008.06.021
24. CH Yang CJ Yu JY Shih YC Chang FC Hu MC Tsai KY Chen ZZ Lin CJ Huang CT Shun CL Huang J Bean AL Cheng W Pao PC Yang 2008 Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy J Clin Oncol 26 2745 2753 18509184 10.1200/JCO.2007.15.6695 1:CAS:528: DC%2BD1cXnvVOhtr8%3D